Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed.

J Affect DisordJul 1, 2026 (epub)
Clinical ResearchPsychiatry

Leslie Citrome, Zhen Zhang, Anne M Hutson Walker et al.

✦ AI-curated · Sources linked

In 30 seconds

This post hoc analysis of a double-blind, randomized controlled trial evaluated aripiprazole once-monthly 400 mg in patients with bipolar I disorder. At 52 weeks, 73.5% of patients on AOM 400 were free from mood episode recurrence compared to 48.9% on placebo, yielding a number needed to treat (NNT) of 5. The study suggests a favorable benefit-risk profile for AOM 400.

Key findings

  • 73.5% of patients on AOM 400 were free from mood episode recurrence at Week 52 compared to 48.9% on placebo.
  • The number needed to treat (NNT) for AOM 400 was 5 (95% CI: 3, 8).
  • Discontinuation due to treatment-emergent adverse events was lower with AOM 400 (17.4%) than placebo (25.6%).
  • The likelihood to be helped or harmed (LHH) was 200 for patients free from recurrence versus discontinuation due to any TEAE.

Why it matters

Understanding the benefit-risk profile of long-term treatments for bipolar I disorder is crucial for clinicians to make informed decisions about patient management and to optimize therapeutic outcomes.

Source

PubMed · PMID 42379429

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.